Multi-center Study to Transplant Hepatitis-C Infected Kidneys (MYTHIC)

R

Raymond Chung

Status and phase

Completed
Phase 4

Conditions

Hepatitis C
Renal Failure Chronic

Treatments

Drug: glecaprevir/pibrentasvir treatment

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03781726
2018P003140

Details and patient eligibility

About

Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.

Full description

The study objective is to determine if the administration of the direct acting antiviral glecaprevir/pibrentasvir for 8 weeks after kidney transplantation is both safe and effective at preventing the spread of HCV infection from donor kidney with known HCV infection (all genotypes) to an HCV negative recipient as evidenced by a negative HCV viral RNA at 12 weeks post treatment.

Enrollment

30 patients

Sex

All

Ages

21 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Recipient Inclusion Criteria:

  • Estimated glomerular filtration rate(eGFR) < 15 ml/min/1.73 m2
  • Listed for an isolated kidney transplantation
  • Able to understand and adhere to the study visit schedule and all other protocol requirements, and must voluntarily sign and date an informed consent
  • No available medically acceptable, compatible living kidney donor
  • Subject must agree to use an effective method of birth control per protocol specifications

Recipient Exclusion Criteria:

  • History of severe, life-threatening or other significant sensitivity to immunosuppressants utilized in kidney transplant
  • Female who is pregnant, breastfeeding, or is planning to become pregnant during the course of the study
  • History of HIV
  • HCV RNA positive
  • HBV surface Ag-positive or detectable HBV DNA
  • Primary focal segmental glomerulosclerosis (FSGS) or disease process with increased risk of causing early graft failure as assessed by the transplant nephrologist and/or investigator team
  • Presence of clinically significant liver disease
  • Transplant candidate requiring antibody desensitization protocol for transplantation
  • Most recent calculated panel reactive antibody (cPRA) >80%.
  • Prior recipient of a non-renal solid organ transplant

Donor Organ Inclusion Criteria

  • Deceased donor organ with kidney donor profile index (KDPI) ≤0.85
  • HCV RNA-positive

Donor Organ Exclusion Criteria

  • Known prior HCV treatment with direct acting antiviral medication
  • HIV RNA-positive
  • HBV Surface antigen-positive or HBV DNA-positive

Trial design

30 participants in 1 patient group

Treatment with glecaprevir/pibrentasvir Fixed Dose Combination
Experimental group
Description:
8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
Treatment:
Drug: glecaprevir/pibrentasvir treatment

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems